Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BIOTU Stock Summary
In the News
Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021
NEW YORK, March 15, 2021 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOTU) (the "Company") announced that, commencing March 18, 2021, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares ("Class A Ordinary Shares") and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering
New York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Biotech Acquisition Company (the “Company”) announced today that it has closed its initial public offering of 23,000,000 units, including 3,000,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000.
BIOTU Financial details
BIOTU Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2020-12-31 | 2021-12-31 |
---|---|---|---|
2.02K | 2.02K | ||
Revenue per share | 0 | 0 | |
Net income per share | 0 | -0.42 | |
Operating cash flow per share | 0 | -0.05 | |
Free cash flow per share | 0 | -0.05 | |
Cash per share | 0 | 0 | |
Book value per share | 0 | 0 | |
Tangible book value per share | 0 | 0 | |
Share holders equity per share | 0 | 0 | |
Interest debt per share | 0 | 0.18 | |
Market cap | 278.88M | 282.9M | |
Enterprise value | 278.88M | 282.9M | |
P/E ratio | 0 | -23.27 | |
Price to sales ratio | 0 | 0 | |
POCF ratio | 0 | -193.08 | |
PFCF ratio | 0 | -193.08 | |
P/B Ratio | 13.94K | -10.41M | |
PTB ratio | 13.94K | -10.41M | |
EV to sales | 0 | 0 | |
Enterprise value over EBITDA | 0 | -41.21 | |
EV to operating cash flow | 0 | -193.08 | |
EV to free cash flow | 0 | -193.08 | |
Earnings yield | 0 | -0.04 | |
Free cash flow yield | 0 | -0.01 | |
Debt to equity | 3.48 | 0 | |
Debt to assets | 0.78 | 0 | |
Net debt to EBITDA | 0 | 0 | |
Current ratio | 0 | 0.95 | |
Interest coverage | 0 | -0.3 | |
Income quality | 0 | 0.21 | |
Dividend Yield | 0 | 0 | |
Payout ratio | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | |
Research and developement to revenue | 0 | 0 | |
Intangibles to total assets | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | |
Capex to revenue | 0 | 0 | |
Capex to depreciation | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | |
Graham number | 0 | 0 | |
ROIC | 0 | 102.36K | |
Return on tangible assets | 0 | -52.79K | |
Graham Net | 0 | 0 | |
Working capital | -69.5K | -0.01 | |
Tangible asset value | 20K | 202.85 | |
Net current asset value | -69.5K | -27.17 | |
Invested capital | 3.48 | 0 | |
Average receivables | 0 | 0 | |
Average payables | 0 | 0 | |
Average inventory | 0 | 0 | |
Days sales outstanding | 0 | 0 | |
Days payables outstanding | 0 | 0 | |
Days of inventory on hand | 0 | 0 | |
Receivables turnover | 0 | 0 | |
Payables turnover | 0 | 0 | |
Inventory turnover | 0 | 0 | |
ROE | 0 | 447.52K | |
Capex per share | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0.1 | -0.5 | 0.81 | 0.7 | 0.1 | |
Operating cash flow per share | -0.02 | -0.01 | -0.02 | -0.01 | 0 | |
Free cash flow per share | -0.02 | -0.01 | -0.02 | -0.01 | 0 | |
Cash per share | 0.01 | 0 | 0.02 | 0 | 0 | |
Book value per share | 7.31 | -0.95 | -3.91 | -0.46 | -0.46 | |
Tangible book value per share | 7.31 | 7.06 | 36.09 | 7.54 | 7.59 | |
Share holders equity per share | 7.31 | -0.95 | -3.91 | -0.46 | -0.46 | |
Interest debt per share | 0 | 0.24 | 0 | -0.37 | -0.05 | |
Market cap | 280.03M | 282.9M | 56.7M | 284.63M | 285.2M | |
Enterprise value | 279.62M | 282.81M | 56.59M | 284.62M | 285.19M | |
P/E ratio | 23.8 | -4.97 | 3.03 | 3.55 | 25.74 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -523.66 | -909.68 | -554.04 | -1.18K | -1.99K | |
PFCF ratio | -523.66 | -909.68 | -554.04 | -1.18K | -1.99K | |
P/B Ratio | 1.33 | -10.41 | -2.52 | -21.29 | -21.74 | |
PTB ratio | 1.33 | -10.41 | -2.52 | -21.29 | -21.74 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 95.05 | -38.82 | -29.83 | 30.33 | 226.08 | |
EV to operating cash flow | -522.91 | -909.38 | -553.02 | -1.18K | -1.99K | |
EV to free cash flow | -522.91 | -909.38 | -553.02 | -1.18K | -1.99K | |
Earnings yield | 0.01 | -0.05 | 0.08 | 0.07 | 0.01 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -0.14 | 0.01 | 0.05 | 0 | -0.01 | |
Current ratio | 1.88 | 0.95 | 0.14 | 0.04 | 0.03 | |
Interest coverage | 0 | -0.05 | 0 | 0.12 | 0.16 | |
Income quality | -0.18 | 0.04 | -0.02 | -0.02 | -0.11 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.1 | 3.25 | 8.46 | 2.7 | 0.99 | |
ROIC | 0 | 0.02 | 0.08 | 0.2 | 0.04 | |
Return on tangible assets | 0.01 | -0.06 | 0.02 | 0.09 | 0.01 | |
Graham Net | -0.7 | -0.95 | -3.95 | -0.47 | -0.46 | |
Working capital | 315.61K | -14.35K | -1.91M | -3.18M | -3.42M | |
Tangible asset value | 210.14M | 202.85M | 207.53M | 216.91M | 218.17M | |
Net current asset value | -19.88M | -27.17M | -22.51M | -13.37M | -13.12M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 178.84K | 178.84K | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 51.11 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 1.76 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.01 | 0.52 | -0.21 | -1.5 | -0.21 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BIOTU Frequently Asked Questions
What is Biotech Acquisition Company stock symbol ?
Biotech Acquisition Company is a US stock , located in New york of Ny and trading under the symbol BIOTU
What is Biotech Acquisition Company stock quote today ?
Biotech Acquisition Company stock price is $10.14 today.
Is Biotech Acquisition Company stock public?
Yes, Biotech Acquisition Company is a publicly traded company.